Homelike Care Models Improve Resident Autonomy
Implementation of homelike models in long-term care settings remains inconsistent across facilities, with adoption and sustainability heavily influenced by organizational, staffing, and environmental factors. Understanding barriers and facilitators is essential for designing systems that support resident autonomy and quality of life in aging populations.
Ultra-processed foods impair sperm quality independent of weight
A controlled feeding study in young men demonstrates that ultra-processed food consumption impairs sperm quality and reproductive hormone profiles within weeks, independent of weight gain. This finding clarifies a direct mechanistic pathway between food quality and male fertility—a critical but underexplored link in longevity-focused clinical practice.
Housing Stability Restores Veteran Health Trajectories
Homelessness among veterans aged 55 and older increased 150% between 2010 and 2023, driven by aging, disability, and inadequate housing infrastructure. Supported housing programs like HUD-VASH demonstrate efficacy, but scaling these interventions requires structural policy changes and sustained resource allocation to prevent accelerating health decline in this vulnerable population.
p75 receptor preserves muscle strength aging
p75 neurotrophin receptor activation preserves the structural integrity of neuromuscular junctions and maintains muscle strength throughout aging. This mechanism represents a pathway through which neural-muscle communication can be sustained, directly opposing the decline in force production that typically accompanies advancing age.
Isolation Triggers Inflammatory Oxylipin Surge in Aging
Social isolation in aged mice triggers a substantial increase in lipoxygenase-derived oxylipins, pro-inflammatory lipid mediators that amplify systemic inflammation. This finding establishes a direct biochemical pathway linking psychological stress to accelerated aging through altered lipid metabolism and immune dysregulation.
Sex-Specific Biology Reshapes Longevity Medicine
Healthcare systems designed around male physiology as default have created parallel blind spots for both women and men, undermining the personalization claims central to longevity medicine. Addressing sex-specific biology, diagnostic gaps, and equitable access is foundational to advancing longevity outcomes across populations.
Dendritic Cell Reprogramming Drives Durable Tumor Rejection
Researchers engineered mRNA therapies that reprogram dendritic cells to enhance T cell activation against cancer, achieving complete tumor regression in preclinical models while establishing durable immune memory. This approach targets intracellular signaling pathways rather than relying on external cytokine signals, addressing a fundamental limitation in current immunotherapy.
TrkA modulation: precision pain relief without joint deterioration
AlzeCure's ACD137, a selective TrkA receptor modulator, demonstrates analgesic efficacy in preclinical models while showing signs of joint protection—a combination absent in broader NGF inhibitors. This represents a mechanistic shift toward pain management that may address both symptom and disease progression in osteoarthritis.
DEXA standardization essential for longevity tracking
DEXA body composition scanning has moved from clinical obscurity into mainstream longevity medicine, but rapid commercialization has created a quality control problem. Fitnescity Health's Clinical Integrity Standard addresses this by establishing voluntary benchmarks for testing environment stability, quality assurance, and clinical oversight—critical factors for reliable longitudinal tracking.
APOE2 Protects Neurons Through DNA Repair, Not Just Lipid Metabolism
APOE2, the longevity-associated variant of the apolipoprotein E gene, preserves neuronal DNA integrity and resists cellular senescence through enhanced DNA repair pathways, while APOE4 shows transcriptional signatures linked to neurodegeneration. This mechanism shifts understanding of Alzheimer's genetic risk from lipid metabolism alone to the fundamental capacity of neurons to maintain genomic order under cumulative stress.
RNA Editing Rewrites Cancer Cell Instructions Without Permanent DNA Change
RNA editing therapy RZ-001 received FDA fast-track designation for hepatocellular carcinoma, signaling regulatory confidence in programmable medicine approaches that correct cellular instructions rather than permanently altering DNA. This advancement reflects a broader shift toward precision interventions that address age-related disease mechanisms at the molecular level.
Engineered macrophages reverse fibrosis in liver disease models
Resolution Therapeutics presented preclinical evidence that RTX001, an engineered macrophage therapy, reduces liver inflammation, fibrosis, and enzyme elevation in mouse models. The data support progression toward Phase I/II human trials, positioning cell-based immunomodulation as a potential intervention for advanced liver disease.
Blood Biomarkers Enable Neurodegeneration Detection Years Before Symptoms
NeuroVision's acquisition of Durin Life Sciences combines blood-based biomarker detection with retinal imaging and telehealth platforms to enable earlier identification of neurodegenerative diseases—potentially years before symptom onset. This integration positions the combined entity to move from reactive diagnosis toward proactive intervention in Alzheimer's, Parkinson's, and ALS.
MKK4 Inhibition Accelerates Liver Regeneration After Hepatectomy
Darizmetinib, an MKK4 inhibitor, accelerates hepatocyte protection and liver regeneration following surgical resection in preclinical models. Phase 1b interim data presented at EASL 2026 demonstrates potential to prevent post-operative liver failure and expand surgical eligibility in patients with insufficient future liver remnant.
Senescent cell clearance halts lung disease in preclinical model
HCW11-040, a pembrolizumab-derived immunotherapeutic, prevented bronchopulmonary dysplasia in preclinical models by eliminating oxygen-induced senescent cells and restoring exhausted immune function. This represents a potential first-in-class intervention for a rare pediatric lung disease affecting 10,000–15,000 U.S. infants annually, with IND filing anticipated in late 2027.
Tau-Targeting Therapy Slows Cognitive Decline in Early Alzheimer's
Diranersen, an antisense oligonucleotide targeting tau pathology, demonstrated cognitive slowing and robust biomarker reductions in early Alzheimer's disease across all doses in the Phase 2 CELIA trial, with the lowest dose showing the most favorable clinical profile. This represents the first randomized evidence that tau-directed monotherapy can produce both measurable neuropathological and functional benefits in early disease.
Klotho Cell Therapy Restores Aging Protein via Encapsulation
Avaí Bio will present clinical data on an encapsulated cell therapy designed to restore circulating α-Klotho, a protein implicated in aging and metabolic regulation. The approach uses Austrianova's Cell-in-a-Box technology to sustain Klotho production, addressing a mechanism that declines with age and correlates with multiple age-related pathologies.
7-Ketocholesterol Clearance: First Human Evidence of Selective Removal
Cyclarity's UDP-003, an engineered cyclodextrin, successfully mobilized and excreted 7-ketocholesterol in humans for the first time, with favorable safety and pharmacokinetic profiles in Phase 1. This represents a mechanistic approach to removing a cholesterol metabolite implicated in atherosclerosis progression and cardiovascular disease.
Vaginal aging biomarkers shift diagnosis from symptoms to measurable change
Vaginal aging involves measurable molecular changes that can be tracked through specific biomarkers, shifting the clinical understanding from subjective symptom reporting to objective biological assessment. This reframes reproductive aging as a systemic process with identifiable markers relevant to overall healthspan and quality of life.
APOE variants shape brain protein patterns before neurodegeneration
APOE ε2 and ε4 genetic variants produce distinct proteomic signatures that emerge before amyloid accumulation, mechanistically explaining their opposing effects on Alzheimer's disease risk. This proteomic mapping offers a foundation for identifying intervention points specific to genetic risk profiles rather than treating all cognitive decline uniformly.
Half of supplements fail accuracy; verification closes longevity gap
Function's acquisition of SuppCo integrates supplement verification with biomarker testing, addressing a critical gap in wellness accountability. Roughly half of top-selling supplements fail label accuracy standards, yet consumers lack feedback mechanisms to track whether their supplementation is producing measurable effects.
Platform Over Hardware: How Google Health Shifts Wearable Economics
Google's redesign of Fitbit into Google Health repositions wearables as a data platform rather than a subscription product, leveraging AI-powered coaching to interpret health signals for users. This shift threatens the business models of standalone wearable companies by commoditizing their core tracking functions within a larger software ecosystem.
Alzheimer's biomarkers detectable via home fingerprick test
Researchers demonstrated that self-administered fingerprick blood tests for Alzheimer's biomarkers (p-tau217 and GFAP) correlate reliably with cognitive decline and match clinic-based results, removing accessibility barriers to early risk identification. The strong association between elevated GFAP and cardiovascular disease reinforces that neurological aging cannot be separated from systemic health.
Precision Cell Elimination: CRISPR's Selective Cancer-Killing Mechanism
A newly discovered CRISPR system called Cas12a2 identifies cancer cells by their specific RNA signatures and triggers cellular self-destruction while sparing healthy tissue. This represents a shift from gene-editing approaches toward precision elimination of diseased cells, with implications for both cancer treatment and age-related cellular dysfunction.
UDP-003 Clears 7KC Through Urine, Restores Macrophage Function
Cyclarity's UDP-003 completed Phase 1 safety testing in 72 healthy volunteers, demonstrating excellent tolerability with no serious adverse events and achieving its primary mechanism: selective extraction of 7-ketocholesterol (7KC), a toxic oxidized cholesterol variant, into urine. The compound targets the root cause of atherosclerosis by converting dysfunctional foam cells back into active macrophages capable of clearing arterial plaque.
7-Ketocholesterol Removal Reverses Plaque Buildup
Cyclarity's UDP-003 demonstrates the first clinical evidence that 7-ketocholesterol, a primary driver of atherosclerotic plaque formation, can be safely targeted and excreted from the human body. This represents a shift from managing cardiovascular disease progression to potential plaque reversal, with even modest reductions in plaque burden associated with significantly lower cardiovascular event risk.
GPR6 inhibitor reduces Parkinson's OFF-time without dopamine toxicity
CereVance completed enrollment of 341 participants in a Phase 3 trial testing solengepras, a non-dopaminergic GPR6 inhibitor for Parkinson's motor fluctuations. The drug targets OFF-time reduction through a mechanism distinct from conventional dopamine-based therapies, addressing a significant gap in current treatment options for advanced motor dysfunction.
Gene therapy reduces Alzheimer's tau protein 64% in primates
A single intravenous dose of VY1706, a gene therapy targeting tau protein, reduced tau levels by up to 64% in primate brain regions 13 weeks after administration with no observed toxicity at tested doses. This represents a potential disease-modifying approach for tauopathies, with human trials planned for late 2026 pending regulatory approval.
Ribupatide dual agonist advances to Phase 3 obesity trials
Hengrui Pharma and Kailera Therapeutics will present Phase 1 and Phase 2 clinical data for ribupatide, a dual GLP-1/GIP receptor agonist in development as both oral and injectable formulations for obesity treatment. The Phase 1 bridging study results supported advancement to Phase 3 trials, positioning ribupatide as a potential therapeutic option with emphasis on weight loss efficacy and tolerability.
Prefrontal Neurotransmitter Remodeling Across Aging and CNS Disease
Integrating over 1 million single-cell sequencing datasets from the prefrontal cortex reveals cell-type-specific alterations in neurotransmitter systems across aging and eight neuropsychiatric disorders. These dysregulated patterns differ by disease and sex, identifying mechanisms that could guide therapeutic targeting and establish a foundation for precision medicine approaches in CNS disease.
Muscle Mitophagy Suppresses Systemic Aging via ROS Control
Muscle mitophagy—the selective removal of damaged mitochondria—declines with age and triggers inflammatory signaling that accelerates systemic aging and neurodegeneration. Enhancing BNIP3-mediated mitophagy in muscle suppresses this inflammatory cascade, extends lifespan, and protects brain tissue from age-related pathology in model organisms.
Glutamine pathway loss drives aged muscle stem cell dysfunction
Aging muscle stem cells lose their capacity to use glutamine for lipid synthesis through reductive TCA cycling, a metabolic pathway essential for activation. Restoring this pathway represents a tractable intervention point against age-related muscle loss and functional decline.
ULK1 Restores Cellular Cleanup in Alzheimer's Models
Elevated ULK1 expression enhances autophagy and mitophagy pathways, reducing amyloid and tau accumulation while delaying cognitive decline in Alzheimer's models. This positions cellular cleanup mechanisms as a direct target for disease modification rather than symptomatic management.
Metal Ion Imbalance Drives Age-Related Eye Disease
Dysregulation of metal ion homeostasis—particularly iron, copper, and zinc—drives age-related ocular pathology through oxidative stress and protein aggregation. Restoring metal ion balance emerges as a tractable intervention point for diseases including macular degeneration and cataracts.
Gait patterns reveal early cognitive decline before symptoms
Individuals at risk of cognitive impairment show distinct neural patterns when performing simultaneous walking and cognitive tasks, revealing early markers of cognitive decline before symptomatic presentation. This finding establishes gait-cognition coordination as a measurable biomarker for identifying those who may progress to pathological cognitive loss.
Sleep Duration Outside 6.4–7.8 Hours Accelerates Organ Aging
Sleep duration outside 6.4–7.8 hours per night accelerates aging across 17 organ systems, with both short sleep (<6 hours) and long sleep (>8 hours) driving measurable deterioration in cardiovascular, respiratory, and immune function. This U-shaped relationship, derived from half a million participants, positions sleep as a modifiable variable with direct impact on biological aging rates across multiple physiological systems.
APOE2 DNA Repair Mechanism Explains Neuronal Longevity
The APOE2 gene variant protects neurons through enhanced DNA repair mechanisms and resistance to cellular senescence, independent of its traditional role in lipid metabolism. This finding redirects therapeutic strategy toward genomic stability as a primary driver of neuronal longevity and dementia prevention.
Longevity Academy expands clinical curriculum
Longevity Academy has expanded its clinical curriculum to bridge the gap between aging science and practical patient care, addressing the field's critical need for structured medical education that translates theory into responsible clinical practice. The program trains physicians in diagnostics, patient communication, operational workflows, and evidence-based intervention—moving beyond biomarker enthusiasm toward repeatable, credible care delivery.
WHOOP moves into clinical care as Fitbit rebrands to Google Health
Wearable platforms are transitioning from passive data collection to clinical integration, with WHOOP launching telehealth services that connect continuous biometric monitoring to medical records and clinical interpretation. This shift addresses a fundamental gap in current health monitoring: the ability to contextualize patterns within a broader clinical picture and detect meaningful health changes before they become acute problems.
Monthly obesity shot moves closer to reality
MBX Biosciences reported early Phase 1 data for MBX 4291, a monthly injection designed to deliver steady drug release with reduced gastrointestinal side effects compared to current weekly GLP-1 treatments. The approach addresses a critical barrier to treatment sustainability: adherence through improved tolerability and dosing convenience.
Restore taps into consumer NAD+ interest
NAD+ awareness has transitioned from niche biohacker circles to mainstream consumer interest, with companies like Restore positioning supplementation as a long-term cellular maintenance strategy rather than a rapid intervention. The shift reflects a maturing longevity market moving away from anti-aging hype toward evidence-informed consistency.
Current Clinical Trials of Alzheimer’s Drugs
Clinical trials for Alzheimer's disease have expanded significantly, with 158 drugs across 192 trials currently under investigation. The pipeline reflects a strategic shift toward multi-target approaches, particularly inflammation and immune dysfunction alongside established amyloid and tau pathways, reflecting recognition that cognitive decline involves multiple biological mechanisms requiring coordinated intervention.
Age‐Associated Impairment of Paneth Cells Driven by microRNA‐152 Promotes Intestinal Epithelial Vulnerability to Pathological Stress
Aging drives dysregulation of microRNA-152 in the small intestine, which impairs Paneth cells by suppressing mitochondrial function—specifically through reduced expression of Prohibitin1. This mechanism directly compromises intestinal barrier integrity and increases vulnerability to infection and injury in older adults.
MAK‐2 Kinase Is Required for Extended Longevity and Enhanced Stress Resistance Resulting From Mild Impairment of Mitochondrial Function in isp‐1 Mutants
Mild impairment of mitochondrial function extends lifespan in C. elegans through kinase signaling pathways—particularly MAK-2—that translate mitochondrial stress into nuclear gene expression changes favoring stress resistance and cellular resilience. This demonstrates that longevity benefits from metabolic compromise depend on intact signaling between mitochondria and nucleus, not simply on reduced energy output.
Sironax receives FDA fast track status for neuroprotective SARM1 inhibitor
Sironax's SIR2501, a first-in-class allosteric SARM1 inhibitor, received FDA Fast Track designation for chemotherapy-induced peripheral neuropathy, a serious complication of cancer treatment with limited therapeutic options. The mechanism preserves nerve function by maintaining SARM1 in an inactive state, with Phase 1b/2 trials underway in CIPN and ALS.
Lysoway begins Phase 1 trial for neurodegenerative disease treatment
Lysoway Therapeutics has initiated Phase 1 testing of LW-1017, a small-molecule TRPML1 agonist designed to restore autophagy-lysosomal function in neurodegenerative diseases including Alzheimer's and Parkinson's. The compound represents a potential intervention targeting cellular waste clearance mechanisms that decline with age.
Function acquires SuppCo to add independent supplement testing and tracking
Function acquired SuppCo to integrate independent supplement verification into its clinical platform, addressing a critical gap: approximately half of top-selling supplements fail basic label accuracy standards. This merger combines third-party testing infrastructure with personalized health tracking and clinician oversight.
New ALS therapy COYA 302 moves toward expedited FDA review
COYA 302, a biologic combination of low-dose interleukin-2 and CTLA-4 Ig designed to modulate immune tolerance, has received FDA Fast Track designation for ALS treatment. The therapy targets regulatory T cell function and suppresses pro-inflammatory monocyte and macrophage activation, addressing a mechanism implicated in motor neuron degeneration.
MetaVia to present high-dose obesity drug data at major liver congress
MetaVia will present Phase 1 safety and pharmacokinetic data for DA-1726, a once-weekly GLP-1/glucagon dual agonist, at the European Association for the Study of the Liver Congress in May 2026. Preclinical evidence suggests potential advantages over existing weight-loss agents in weight reduction, glucose control, and lean mass preservation, with particular relevance to metabolic dysfunction-associated liver disease.
Ribo, Insilico partner to accelerate siRNA drug development using AI
Ribo and Insilico Medicine are collaborating to accelerate siRNA drug development by combining siRNA capabilities with AI-powered target discovery and molecule design. siRNA therapeutics can selectively silence disease-causing genes with rapid development timelines and extended therapeutic duration.
Additional Cover
APOE2, a rare genetic variant associated with exceptional longevity, activates cellular signaling pathways in neurons that resist senescence and maintain regenerative capacity. This finding identifies a molecular mechanism through which genetic variants can extend healthspan by preserving neuronal function and preventing age-related cellular decline.
Who Are the Long-Term and Short-Term Users of Meals on Wheels Services in the 65+ US Population?
This study categorizes older adults using Meals on Wheels services into long-term and short-term users, revealing distinct patterns across socioeconomic and health status variables. Understanding these usage patterns informs how meal support programs serve populations with differing nutritional vulnerability and resource constraints.
Mirroring tissue senescence in human biofluids
Researchers have developed a non-invasive urine-based biomarker panel to monitor cellular senescence and track the efficacy of senolytic therapies. This approach enables real-time assessment of senescent cell burden without tissue biopsy, creating a practical pathway for personalized intervention monitoring in aging-related disease.
Urinary detection of therapy-induced senescence and fibrosis using an injectable albumin-based nanoprobe
Researchers developed an injectable nanoprobe that detects cellular senescence through urine analysis, using MMP-7 enzyme activity as a measurable marker. This enables non-invasive, real-time monitoring of treatment response in lung cancer and pulmonary disease, establishing a quantifiable method to track senescence burden during therapy.
Region-specific transcriptional signatures of brain aging in the absence of neuropathology at the single-cell level
Single-cell transcriptional analysis reveals region-specific aging signatures in the brain that occur independently of classical neuropathology, suggesting aging involves coordinated transcriptional changes across distinct neural populations. This finding establishes a molecular basis for understanding how brain regions age differently and may identify intervention points before pathological hallmarks emerge.
Reproductive life events and biological aging in women over 50: evidence from DNA methylation clocks
Reproductive life events—including age at menarche, menopause timing, and pregnancy history—correlate with biological aging rates in women over 50, as measured by DNA methylation clocks. These associations suggest that hormonal exposure patterns across the lifespan accumulate physiological debt that manifests as measurable differences in aging velocity.
NAD+ webinar set to examine delivery dilemma
NAD+ delivery methods—pills, injections, and pens—are receiving increased clinical scrutiny as the molecule transitions from niche longevity therapy to mainstream wellness category. The effectiveness of NAD+ depends less on the molecule itself than on bioavailability, formulation quality, and whether patients maintain consistent use.
Abu Dhabi opens a real-world test lab for longevity
Abu Dhabi is establishing an integrated health infrastructure that combines clinical records, genetic data, and continuous wearable monitoring into a real-time evidence system designed to shift healthcare from reactive treatment to predictive intervention. This represents a systematic approach to testing longevity interventions within functioning health systems rather than isolated research environments.
Clene gets FDA nod for ALS accelerated path
The FDA has signaled that Clene's CNM-Au8, a therapy targeting neuronal energy metabolism in ALS, may qualify for accelerated approval based on neurofilament light (NfL) as a biomarker for neurodegeneration. This regulatory pathway compresses timelines for a disease where traditional efficacy endpoints are incompatible with disease progression rates.
Longevity risk at the individual level
Longevity extends exposure to health shocks, care disruption, and systemic strain—making it fundamentally a risk-horizon problem rather than a retirement finance problem. European care systems face critical workforce shortages that will compress healthspan and financial security simultaneously, particularly as informal care networks continue to deteriorate.
New COSRX peptide serum taps growing skin longevity market
COSRX's Blue Peptide Bakuchiol serum addresses emerging consumer demand for skin resilience and long-term health rather than antiaging reversal, specifically acknowledging how body composition changes—including from GLP-1 medications—affect facial firmness and elasticity. The product democratizes peptide-based skincare by making copper tripeptide-1 accessible at mid-market price points rather than luxury positioning.
Forever Healthy Releases AI4L 1.0 for Practical Longevity
Forever Healthy released AI4L 1.0, an open-source system using Audit-Driven Prompting to generate evidence-based reviews of longevity interventions with live citation verification and zero-tolerance quality gates. This addresses the scalability problem of evaluating a fragmented landscape of senolytic, metabolic, and peptide-based therapies where evidence is dispersed across journals and clinical trials.
GLP-1 Drugs’ Muscle Effects Similar to Ordinary Weight Loss
GLP-1 receptor agonists produce weight loss with lean body mass reduction comparable to caloric restriction alone, with minimal impact on muscle function. The reduction in lean body mass appears driven largely by liver mass loss rather than skeletal muscle depletion.
LifespanningRx expands regenerative offering with RegenTherapy
LifespanningRx and RegenTherapy have partnered to integrate CellGen Factors—a cell signaling technology platform—into a consumer-accessible longevity program. The collaboration combines commercial infrastructure with clinical regenerative medicine expertise to deliver structured protocols for cellular recovery and performance optimization.
MBX Biosciences reports 7% weight loss in preliminary Phase 1 trial of MBX 4291
MBX Biosciences reports 7% mean weight loss over eight weeks with MBX 4291, a GLP-1/GIP co-agonist prodrug, in a preliminary Phase 1 cohort with favorable tolerability. The pharmacokinetic profile supports once-monthly dosing, positioning this approach as a potential alternative to existing weekly GLP-1 therapeutics for weight management.
Vasa Therapeutics targets 2026 clinical entry for peripheral artery disease therapy
Vasa Therapeutics is advancing VS-214, an apelin peptide analog designed to promote new blood vessel formation and improve blood flow in peripheral artery disease patients, toward first-in-human trials in 2026. PAD affects 10–12 million Americans and causes approximately 400 non-traumatic amputations daily, representing a significant clinical need for pharmacological intervention.
PST-611 Phase 1 data shows inflections in geographic atrophy growth
PST-611, a transferrin-encoding gene therapy targeting iron dysregulation in dry age-related macular degeneration, demonstrated safety and tolerability in a six-patient Phase 1 trial with encouraging signals of slowed geographic atrophy progression. The therapy addresses a mechanistic pathway implicated in retinal degeneration, with Phase 2a development initiated for 2026.
Fractyl Health gains approval for first GLP-1 gene therapy trial
Fractyl Health initiated a Phase 1/2 trial of RJVA-001, an adeno-associated virus gene therapy designed to restore physiologic GLP-1 production within the pancreas in adults with inadequately controlled type 2 diabetes. This represents the first human application of localized pancreatic gene therapy for glucose regulation, addressing the pharmacokinetic and metabolic limitations of systemic GLP-1 receptor agonists.
The MICOS Complex Regulates Mitochondrial Structure and Oxidative Stress During Age‐Dependent Structural Deficits in the Kidney
The MICOS complex, a structural regulator of mitochondrial cristae, deteriorates with age in kidney tissue, leading to fragmented mitochondria, elevated oxidative stress, and impaired energy metabolism. This structural collapse represents a discrete mechanism linking cellular aging to the progressive loss of kidney function observed in older adults.
Tissue softness unlocks regeneration
Tissue mechanical properties—specifically softness—regulate regenerative capacity in aging organisms. This finding reframes age-related decline not as inevitable cellular exhaustion but as a mechanical constraint that can be modulated, with direct implications for extending healthspan through structural optimization.
Somatic variants in microglia-like cells linked to Alzheimer’s disease pathology
Somatic mutations accumulating in microglia—brain immune cells—correlate with Alzheimer's disease pathology and cognitive decline. These acquired genetic variants, distinct from inherited risk factors, represent a previously underappreciated mechanism driving neurodegeneration and suggest new intervention points before symptomatic disease emerges.
Brain endothelial cell-derived extracellular vesicles (c-BEEVs) as a promising biomarker for brain vascular pathology and cognitive decline
Brain endothelial cell-derived extracellular vesicles (c-BEEVs) detected in cerebrospinal fluid serve as a measurable biomarker for vascular dysfunction affecting the brain and cognitive decline. This discovery enables earlier detection of neurovascular pathology before symptomatic cognitive loss.
Hypoxia-induced autophagic degradation of HIF-1α attenuates cellular aging and extends mammalian lifespan
Intervertebral discs age slowly due to selective autophagy of HIF-1α under naturally hypoxic conditions. A small molecule designed to replicate this mechanism across tissues may extend mammalian lifespan by modulating how cells respond to low-oxygen environments.
Aging dictates tumor-specific genomic alterations across cancer types
Aging systematically reshapes the genomic landscape of tumors across cancer types, with age-dependent mutations and chromosomal alterations that diverge from patterns seen in younger patients. This finding reframes cancer as partly an age-driven disease of accumulated cellular errors, with direct implications for prevention, detection, and treatment stratification based on age-related biology.
The brain doesn’t have to decline
Cognitive decline is increasingly recognized as preventable and reversible through targeted cognitive training and integrated lifestyle interventions, rather than an inevitable consequence of aging. A landmark 20-year study found that speed-processing training reduced dementia incidence by 25%, while clinical cases demonstrate substantial cognitive recovery when multiple physiological and psychological factors are addressed simultaneously.
Hospitals confront longevity’s quiet disruption
Hospital systems designed for acute crisis intervention face structural barriers to adopting longevity-focused prevention, requiring fundamental shifts in incentive structures, data integration, and measurement of success. The transition demands more than clinical protocol changes—it requires cultural reorientation toward longitudinal patient stewardship rather than episodic treatment.
Scarlet raises $4m as lab-grown blood matches donor cell survival
Scarlet Therapeutics has demonstrated that laboratory-grown red blood cells survive in circulation as long as donor-derived cells, validating a platform for scalable cell manufacturing and therapeutic delivery. This represents a critical proof-of-concept for replacing donor-dependent blood supply with engineered cells capable of both oxygen transport and targeted therapeutic function.
AI regenerative medicine targets skin recovery
ROKIT Healthcare presented two-year clinical data on AI-driven bioprinting for skin cancer reconstruction using patients' own fat cells, demonstrating 0% recurrence, restored function and sensation, and minimal scarring. This represents a shift in how medicine approaches post-surgical recovery—from wound closure alone to restoration of tissue architecture and sensory integrity.
Abu Dhabi’s “Future Health” initiative targets longevity, predictive care
Abu Dhabi is establishing a large-scale health infrastructure combining genomic, phenotypic, and wearable data with AI to enable predictive care and accelerate drug discovery. This represents a shift toward population-level early detection and prevention rather than reactive treatment models.
Function Health pushes comprehensive diagnostics, hormone testing
Function Health positions comprehensive lab testing—160+ markers including metabolic and hormonal panels—as a foundation for preventive health monitoring, with emphasis on insulin, cortisol, thyroid, and leptin assessment to detect metabolic dysregulation earlier than standard screening. The model links biomarker tracking to lifestyle factors to inform individualized health optimization and support longitudinal monitoring.
Annovis Bio to discuss multi-protein approach to Alzheimer’s
Annovis Bio is advancing buntanetap, an oral therapy targeting multiple neurotoxic proteins implicated in Alzheimer's disease, moving beyond the single-protein paradigm that has dominated the field. This multi-target approach addresses a fundamental gap between pathophysiological evidence and current therapeutic strategy, with Phase 3 data supporting both clinical benefit and biomarker improvement.
FDA extends priority review for Leqembi subcutaneous starting dose
The FDA extended priority review for Leqembi subcutaneous starting dose to August 2026 following a request for additional information. The decision does not reflect approvability concerns and follows approval of subcutaneous maintenance dosing in August 2025.
Longeveron loses pivotal designation as FDA questions endpoints
The FDA withdrew its pivotal designation for Longeveron's ELPIS II trial of laromestrocel in infants with hypoplastic left heart syndrome, citing insufficient evidence that the primary endpoint (right ventricle ejection fraction) demonstrates clinical efficacy. The agency recommended shift toward objective outcomes including mortality, transplant-free survival, and major adverse cardiac events.
Quantitative mapping detects progressive iron accumulation in early MSA
Quantitative susceptibility mapping has identified progressive iron accumulation as a detectable marker in early multiple system atrophy, enabling earlier disease staging and potential therapeutic intervention windows. This advances diagnostic precision in a neurodegenerative condition where iron dysregulation contributes to neuronal dysfunction and cell death.
Rznomics receives FDA RMAT status for RNA-editing HCC candidate
Rznomics' RZ-001, an RNA-editing therapeutic targeting hepatocellular carcinoma, received FDA Regenerative Medicine Advanced Therapy designation based on Phase 1b/2a safety and efficacy data. This regulatory milestone accelerates development pathways for a precision oncology candidate using trans-splicing ribozyme technology to selectively target cancer cells.
FAM162A Is a Key Regulator of Mitochondrial Structure, Dynamics, and Bioenergetics, Driving Cellular Protection and Longevity
FAM162A, a mitochondrial cristae protein, regulates mitochondrial structure and energy production through interaction with OPA1, enhancing cellular stress resistance and extending lifespan in model organisms. This identifies a previously unrecognized mechanism linking mitochondrial dynamics to organismal longevity.
Featured Cover
Spatiotemporal transcriptomic analysis reveals how immune cell populations shift and reorganize within liver tissue during aging, exposing distinct microenvironmental changes that precede functional decline. These findings establish a molecular map of immunological aging in a primary metabolic organ, with implications for understanding how local immune dysregulation contributes to age-related disease susceptibility.
Exosome‐Delivered eNAMPT From Exercise Activates SIRT1 to Counteract Age‐Related Hepatic Steatosis and Fibrosis
Exercise triggers release of exosome-delivered eNAMPT, which activates hepatic SIRT1 and autophagy to reverse age-related fatty liver disease, inflammation, and fibrosis in aged mice. This mechanism establishes a biochemical pathway through which physical activity protects metabolic health during aging.
#391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategy
Colorectal cancer is uniquely interceptable through early screening before malignancy develops, making colonoscopy a critical preventive tool. Personalized screening strategies enable individuals to reduce cancer incidence and mortality through proactive detection and removal of precancerous lesions.
Correction to “The Activation of cGAS‐STING Pathway Causes Abnormal Uterine Receptivity in Aged Mice”
A published correction addresses methodological clarifications in research examining how the cGAS-STING innate immune pathway dysregulates uterine receptivity during aging. The work connects age-related immune activation to reproductive decline in mice, with implications for understanding fertility loss across aging.
The dynamic physiology of the brain with menopause
Brain imaging reveals menopause involves significant neurological changes beyond reproductive shifts, with alterations in cerebral blood flow, neural connectivity, and metabolic function that persist into the post-menopausal years. Understanding these changes is essential for optimizing cognitive function and preventing age-related neurological decline in midlife women.
Exceptional Longevity Modifying Allele APOE2 Promotes DNA Signaling Pathways Resisting Cellular Senescence in Human Neurons
APOE2, a genetic variant associated with exceptional longevity, activates DNA repair pathways and resists cellular senescence in neurons, while APOE4 exhibits elevated DNA damage and senescence markers. This mechanism extends beyond lipid metabolism, explaining APOE2's protective effects against neurodegeneration.
sc-ChromAging: A Single-Cell Chromatin Accessibility-based Clock Decodes Cell-Type-Specific Epigenetic Aging Trajectories
Researchers developed sc-ChromAging, a single-cell epigenetic clock that measures aging at the cellular level by analyzing chromatin accessibility patterns specific to each cell type. This tool reveals that different cells age at different rates and through distinct molecular pathways, offering a method to detect and potentially intervene in age-related cellular dysfunction before systemic decline occurs.
Circulating levels of insulin-like growth factor binding protein 7 are associated with risks of chronic diseases and death
Circulating insulin-like growth factor binding protein 7 (IGFBP7) independently predicts risk of chronic disease and mortality across multiple conditions, suggesting it functions as a systemic biomarker of aging and physiological decline. Measurement of IGFBP7 may offer clinicians a quantifiable indicator of disease susceptibility that extends beyond traditional risk factors.
‘We are not at consensus but we are at convergence’
The longevity field is moving from theoretical frameworks toward measurement-based clinical practice, with epigenetic clocks and multi-omics tools providing quantifiable biological age metrics that enable longitudinal tracking and personalized intervention. Precision assessment is becoming foundational to translating longevity research into actionable clinical protocols.
GLP-1 drug enters trial for progressive multiple sclerosis
A long-acting GLP-1 receptor agonist has entered Phase 2 trials for progressive multiple sclerosis, marking a shift in how researchers view this drug class beyond metabolic disease. The compound targets neuroinflammation and neurodegeneration rather than immune suppression alone, addressing a core limitation of existing MS therapies.
Voyager pushes IV gene therapy for Alzheimer’s
Voyager Therapeutics has demonstrated that engineered gene therapies can reach the brain via intravenous infusion rather than invasive delivery, with preclinical data showing VY1706 achieved safe, predictable distribution to the central nervous system in non-human primates. This addresses a fundamental bottleneck in neurological drug development and positions tau-silencing approaches as candidates for clinical translation in Alzheimer's disease.
SimonMed’s AI imaging expansion targets silent diseases
SimonMed is embedding FDA-cleared AI tools into routine imaging scans to detect silent diseases—cardiovascular disease, bone loss, spinal degeneration—earlier, without additional radiation or scan time. This shifts healthcare from reactive treatment to early detection by extracting actionable insights from imaging data already being captured.
Junyue Cao on How the Body Ages, Cell by Cell
Researchers using single-cell epigenomic profiling across seven million cells from 21 mouse tissues identified that approximately one-quarter of all cell types undergo significant shifts during aging, with many changes coordinated across organs and divergent between sexes. This comprehensive atlas reframes aging research from studying isolated signaling pathways to understanding organism-level cellular reorganization, establishing a foundation for therapies targeting aging mechanisms rather than individual diseases.
AI meets ALS in £7.5 million Longitude Prize
A £7.5 million global challenge prize has awarded £2 million in discovery funding to 20 international teams tasked with identifying new drug targets for amyotrophic lateral sclerosis using artificial intelligence and integrated multi-omics data. The initiative targets the upstream bottleneck in ALS research—mechanistic target identification—rather than late-stage drug development, reflecting a strategic shift toward data-centric, predictive approaches to neurodegenerative disease.
Targeting Hyperoxia‐Induced Cellular Senescence in Developing Human Airway Cells: Senomorphics Versus Senolytics Versus Antioxidants
Moderate hyperoxia induces cellular senescence in developing airway tissue, with lasting consequences for lung function. Three mechanistically distinct interventions—Fucoidan, Dasatinib plus Quercetin, and MitoQ—each mitigate senescence through different pathways, offering potential strategies to prevent hyperoxia-related lung disease in premature infants.
Correction to “Monoamine Oxidase‐A Is a Novel Driver of Stress‐Induced Premature Senescence Through Inhibition of Parkin‐Mediated Mitophagy”
This correction addresses methodological refinements in research demonstrating that monoamine oxidase-A drives stress-induced cellular aging by disrupting the cell's ability to clear damaged mitochondria. The finding clarifies a direct mechanism linking stress response dysfunction to accelerated senescence at the mitochondrial level.
Diathrive, KardiaComplete partner to tackle cardiometabolic risk
Diathrive Health and KardiaComplete have partnered to integrate diabetes management with cardiac monitoring through a coordinated employer-focused platform. This addresses the clinical overlap between type 2 diabetes and cardiovascular disease, offering employers a consolidated approach to cardiometabolic risk reduction.
Neuvasq presents preclinical data for blood-retina barrier repair
Neuvasq's multispecific antibodies—NVQ401 and NVQ501—repair the blood-retina barrier by activating Wnt/β-catenin signaling and neutralizing VEGF, demonstrating efficacy across preclinical retinopathy models. These candidates represent a mechanistic departure from current anti-VEGF therapies and address a significant driver of vision loss in aging populations.
AlzeCure publishes preclinical article on ACD137 for osteoarthritis
AlzeCure's preclinical data demonstrate that ACD137, a selective TrkA negative allosteric modulator, produces analgesic effects comparable to anti-NGF antibodies in models of neuropathic and osteoarthritis-related pain, with evidence of anti-inflammatory and cartilage-protective properties. This mechanism addresses a major driver of degenerative joint disease relevant to healthy aging.
Executive Health program condenses three months of testing into six hours
Biograph's Executive Physical consolidates comprehensive cardiovascular, metabolic, cancer, and neurological screening into a single six-hour appointment using whole-body MRI, advanced CT, and biomarker analysis. This integrated approach identifies significant health findings in approximately 17 percent of participants and demonstrates measurable metabolic improvements in follow-up assessments.
How Intestinal Aging Encourages Harmful Bacteria
Intestinal aging creates a self-reinforcing cycle where the gut barrier weakens, immune function declines, and harmful bacteria replace beneficial species. This shift compromises the production of short-chain fatty acids and other metabolites that support immune regulation, accelerating mucosal dysfunction and systemic inflammation with advancing age.
Heart drug vutrisiran shows steady profile in new analyses
Vutrisiran demonstrates consistent efficacy across diverse patient populations and comorbidities in new Phase 3 analyses, reducing transthyretin production to address ATTR-CM at its source rather than managing downstream cardiac damage. Real-world heterogeneity—including atrial fibrillation, polypharmacy, and sex differences—appears manageable, positioning the therapy as a meaningful intervention in an underdiagnosed progressive disease.
Programmable mRNA startup ParcelBio raises $13m
ParcelBio's platform addresses the durability limitation of first-generation mRNA therapeutics by extending protein expression duration, enabling sustained treatment of chronic diseases rather than episodic intervention. This shift from transient to durable mRNA expression represents a fundamental reorientation toward managing systemic biological states over time—a requirement for addressing the complex, multigenerational processes underlying aging.
New GlycanAge conference pushes inflammaging into care
GlycanAge's landmark conference aims to translate 25 years of inflammaging research into clinical practice by demonstrating that glycan analysis can detect disease risk up to a decade before symptoms emerge. This shift from reactive to anticipatory medicine requires both clinical validation and a fundamental change in how patients and providers interpret asymptomatic risk signals.
Beacon Biosignals is turning sleep into brain diagnostics
Beacon Biosignals has developed a home-based EEG headband that records brain electrical activity during sleep, enabling continuous longitudinal monitoring of neural patterns. This approach shifts brain health assessment from single-point diagnostic snapshots to scalable, repeatable data collection that can detect pathological changes years before symptom onset.
Supporting energy through menopause with NMN
NAD⁺ decline during menopause impairs mitochondrial function and energy production across multiple systems simultaneously. NMN, as a direct NAD⁺ precursor, bypasses rate-limiting steps in NAD⁺ biosynthesis to support cellular energy restoration and repair capacity.
Advantages of Skeletal Muscle Preservation in Settings of Weight Loss
GLP-1 receptor agonists effectively reduce adiposity but simultaneously cause skeletal muscle loss, a consequence that diminishes metabolic efficiency and increases frailty risk in vulnerable populations. Preserving muscle mass during weight loss produces superior long-term metabolic outcomes and functional longevity compared to adiposity reduction alone.
Increasing Access to Caregiver-Friendly Workplaces: Stakeholder Perspectives
This research examines workplace policies and organizational practices that support employed family caregivers, addressing a structural barrier to sustainable caregiving while protecting long-term financial security. The findings are relevant to longevity because financial stress and caregiver burden directly impair health outcomes across multiple physiological systems.
Restore Hyper Wellness kicks off NAD Month to educate on IV, IM therapies
Restore Hyper Wellness is promoting NAD supplementation through IV and intramuscular delivery formats, capitalizing on significant year-over-year increases in consumer search interest for NAD-related therapies. The initiative positions NAD precursors and direct NAD administration as tools for cellular energy optimization, though clinical evidence supporting broad longevity claims remains limited.
Novel epigenetic silencer shows potential as finite therapy for chronic hepatitis B
TUNE-401, a first-in-class epigenetic silencer, demonstrates the ability to suppress hepatitis B virus cccDNA transcription in Phase 1b/2a trials, offering potential as a finite rather than lifelong therapeutic intervention. This represents a shift from indefinite viral suppression to targeted epigenetic modulation that may achieve durable control.
ROKIT Healthcare presents two-year skin cancer regeneration data
ROKIT Healthcare demonstrated a two-year clinical safety and efficacy profile for AI-guided bioprinted autologous fat tissue reconstruction following skin cancer excision, with zero tumor recurrence, restored sensation, and reduced scarring compared to conventional approaches. This represents a shift from reactive scar management to regenerative tissue restoration after oncologic surgery.
Neuraly begins Phase 2 trial for progressive MS treatment
Neuraly has initiated a Phase 2 trial (TAG-MS) evaluating pegsebrenatide, a GLP-1 receptor agonist, in approximately 120 patients with progressive multiple sclerosis. The study measures brain volume changes and neurological markers over 96 weeks, building on preclinical evidence suggesting the drug modulates neuroinflammation and protects neural tissue.
Physical Function and Residential Relocation of Older Adults Living With Chronic Conditions
Mobility difficulty in older adults with chronic conditions predicts residential relocation, with the relationship varying by disease type and functional capacity. Understanding how specific chronic conditions affect physical function and environmental fit is essential for predicting housing transitions and timing interventions.
Race-Stratified Randomized Trial Examining Advance Care Planning Engagement Among Older Adults
A randomized trial compared culturally adapted advance care planning documents with standard state directives in Black American older adults, finding that culturally sensitive approaches may improve engagement with end-of-life planning. The study addresses a documented disparity in advance directive completion among Black populations.
Plug-and-play peptides hit longevity and wellness market
LifespanningRx has launched a plug-and-play platform enabling wellness businesses to offer peptide therapy within 24 hours without inventory management, regulatory overhead, or upfront investment. This model addresses the growing demand for personalized longevity interventions by removing operational barriers and shifting competition from the therapies themselves to seamless delivery infrastructure.
Alector halts Alzheimer’s trial after futility readout
Alector halted its Phase 2 trial of nivisnebart for early Alzheimer's disease after a futility analysis indicated the progranulin-boosting therapy was unlikely to slow cognitive decline meaningfully. The discontinuation underscores that single-target interventions may be insufficient for a disease driven by multiple concurrent pathologies.
Singapore’s clinical turn to longevity care
Singapore's Chi Longevity clinic exemplifies a clinical shift toward prevention and precision health in aging populations, grounded in structured diagnostics and longitudinal biomarker tracking rather than episodic care. This model demonstrates how preventive medicine translates from policy aspiration into operational practice through physician-led assessment pathways and individualized risk stratification.
Allen Law’s moonshot vision for the Longevity Century
Allen Law proposes that extending healthspan—not merely lifespan—is the central health challenge of the 21st century. The infrastructure and systems to support longer, stronger lives exist in scientific literature but remain inaccessible at scale; closing the 9.6-year gap between lifespan and healthspan requires proactive, preventive health built into daily life rather than reactive medicine.
BioAge advances NLRP3 drug for CVD, retinal care
BioAge is advancing BGE-102, an oral NLRP3 inflammasome inhibitor, into Phase 2 trials for atherosclerotic cardiovascular disease and retinal disease based on Phase 1 data showing tolerability and reductions in inflammatory markers. NLRP3 inhibition represents a mechanistic approach to reducing systemic inflammation implicated in multiple age-related conditions.
Clene to file accelerated approval NDA for ALS after FDA meeting
Clene received FDA clearance to pursue accelerated approval for CNM-Au8, a mitochondrial-targeted therapy for ALS, based on neurofilament light (NfL) as a surrogate biomarker. The company plans to submit its NDA in Q3 2026, supported by Phase 2 data showing CNM-Au8's effect on NfL reduction and preliminary evidence of clinical benefit.
Niagen Bioscience launches Niagen Plus telehealth platform
Niagen Bioscience launched Niagen Plus, a telehealth platform delivering prescription-only nicotinamide riboside (Niagen) via at-home subcutaneous injection. The injectable route is positioned to bypass first-pass hepatic metabolism and improve tissue bioavailability compared to oral administration.
GlycanAge to convene experts on inflammaging clinical applications
GlycanAge is hosting a conference with Mayo Clinic to advance clinical applications of glycan-based inflammaging markers, which can detect disease risk patterns up to a decade before symptomatic onset. The event aims to integrate chronic-inflammation testing into routine clinical practice.
Estimating Vascular Age to Evaluate the Association Between Aging and Cardiovascular Disease
Vascular age acceleration, measured through a quantitative model, independently predicts cardiovascular disease risk beyond chronological age, with a 21–25% increased risk in those showing accelerated vascular aging. This metric enables earlier identification of individuals requiring intervention before overt disease manifestation.
Healthy Eating Index, Epigenetic Age Acceleration and Mortality Risk in US Adults
Higher diet quality correlates with slower epigenetic aging and reduced mortality risk in two large U.S. cohorts, with epigenetic age acceleration (GrimAgeEAA) explaining approximately 44% of the diet-mortality association in one cohort. The relationship is partially confounded by physical activity and integrated lifestyle factors, indicating that diet operates within a broader system of behavioral and biological aging pathways rather than in isolation.
Vitalist Bay 2026 set to spotlight longevity’s next phase
Vitalist Bay 2026 will convene researchers, investors, and founders in Berkeley for a concentrated four-day program emphasizing AI-driven drug discovery, biostasis, and longevity science. The event reflects the field's shift toward computational approaches while highlighting a persistent gap between scientific ambition and clinical validation.
Niagen launches telehealth NAD+ injection platform
Niagen Bioscience launched a prescription-only telehealth platform delivering subcutaneous NAD+ injections at home, shifting nicotinamide riboside from over-the-counter supplement to clinician-directed pharmaceutical intervention. The model combines telehealth access with clinical oversight and compounded pharmaceutical-grade dosing, though the clinical evidence supporting NAD+ supplementation for meaningful longevity outcomes remains incomplete.
Creatine Shows Synergy With Exercise in Older Adults
A 16-week trial in 103 older adults (mean age 68) demonstrates that creatine supplementation amplifies the benefits of high-load, velocity-intentional resistance training—particularly in markers of neuroplasticity, oxidative stress, and inflammation—though cognitive gains showed no synergistic effect. This addresses a significant gap in gerontological research, as creatine has been understudied in aging populations where its ATP-enhancing properties could meaningfully support the preservation of fast-twitch muscle function.
Longevity.Technology and AND Capital Ventures launch partnership
Longevity.Technology and AND Capital Ventures announced a strategic partnership integrating AI-enabled market intelligence with operator-led investment strategy to identify growth-stage opportunities in longevity and healthspan innovation. The collaboration addresses market fragmentation by consolidating biotech, financing, clinical pipeline and public market signals into a unified intelligence platform for institutional investors.
The molecules you’ve been ignoring might be aging you
Glycans—sugar molecules attached to proteins and lipids—reflect cumulative biological stress and environmental exposure in ways that precede disease symptoms by years. Unlike fixed genetic risk, glycan patterns shift with inflammation, stress, and lifestyle, offering a measurable window into trajectories of aging before clinical disease emerges.
Lineage presents 3-year OpRegen results in geographic atrophy
Lineage Cell Therapeutics reported sustained visual improvement and retinal structural restoration in geographic atrophy patients three years after a single subretinal injection of RG6501. Treated eyes showed mean gains of 6.2 ETDRS letters with objective evidence of RPE and photoreceptor layer recovery, while untreated fellow eyes declined, suggesting durable disease modification from cell therapy intervention.
Rokit accelerates trials of AI cartilage regeneration platform
Rokit Healthcare is advancing an AI-driven 3D bioprinting platform that regenerates hyaline cartilage using patients' own adipose tissue, printed in real time during surgery. A 13-institution clinical trial with over 100 patients evaluates whether this autologous approach produces more durable cartilage repair than standard procedures while eliminating the need for external cell culture and multiple surgeries.
Alnylam to present new Vutrisiran analyses in Barcelona
Alnylam will present clinical and real-world data on Vutrisiran for transthyretin-mediated amyloid cardiomyopathy at the 2026 European Society of Cardiology congress, including pharmacodynamic analyses, safety outcomes across subgroups, and design of a long-term observational study. The data support Vutrisiran as a first-line treatment that achieves rapid TTR protein knockdown but requires vitamin A supplementation and ophthalmologic monitoring.
Trajectory of Cognitive Decline After Incident Hearing Loss: A 24-year Population-Based Longitudinal Cohort Study
Incident hearing loss accelerates cognitive decline over a 24-year period, with the trajectory of cognitive loss steeper in individuals who develop hearing loss compared to those with stable hearing. The magnitude of cognitive decline attributable to hearing loss appears substantial enough to warrant clinical attention in aging populations.
From “Passive Supplementation” to “Active Repair”: Melatonin Reshapes the Treatment Paradigm for Late‐Onset Hypogonadism by Targeting Leydig Cell Senescence
Melatonin restores testosterone production in aging Leydig cells by addressing oxidative stress and mitochondrial dysfunction, offering a mechanism-based alternative to passive testosterone supplementation. This shift from symptom management to cellular repair has implications for age-related hormonal decline in men.
Aged Gut Microbiota Induces Mucosal Transcriptional Dysregulation, Impairing Immune Surveillance
Aging disrupts intestinal mucosal immunity through a cascade of changes: epithelial barrier weakening, shifts toward pro-inflammatory gut bacteria, dysregulation of immune surveillance cells, and impaired pathogen recognition. This multi-system breakdown creates a mechanistic link between microbial composition and immune dysfunction that directly drives infection susceptibility in older adults.
Adult Social Day Services: A Promising, Yet Underutilized Community-Based Support for Individuals With Alzheimer’s Disease and Related Dementias
Adult social day services provide structured community engagement for individuals with Alzheimer's disease and related dementias, improving quality of life and reducing caregiver burden—yet these services remain underutilized despite evidence supporting their efficacy.
Modifiable risk factors attenuated longevity genetic predisposition on life expectancy in the oldest old
In adults over 80, genetic predisposition for longevity loses predictive power when modifiable risk factors—smoking, physical inactivity, poor diet, excessive alcohol use—remain unaddressed. This demonstrates that behavioral interventions can substantially offset inherited longevity advantages in the oldest-old population.
Buntanetap gains ground in new Alzheimer’s trial results
Buntanetap showed statistically significant cognitive improvements in early-stage Alzheimer's patients who tested positive for pTau217, reducing multiple disease-related biomarkers including tau, TDP-43, and neuroinflammatory signals. The drug's mechanism of blocking protein production upstream in the disease cascade, rather than targeting single endpoints, represents a shift toward earlier intervention and suggests the field is moving toward precision treatment based on underlying pathology rather than symptom presentation alone.
Sugar’s hidden role in skin aging revealed
Sugar disrupts skin cells at the functional level, pushing them into senescence and chronic inflammation rather than simply damaging collagen structure. This cellular dysfunction mirrors aging patterns throughout the body, positioning dietary sugar management as foundational to longevity rather than cosmetic skin care.
The first personalized brain repair for Parkinson’s
Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.
Alterity’s neurodegenerative drug moves toward Phase 3
Alterity Therapeutics received FDA approval to advance ATH434 into Phase 3 trials for Multiple System Atrophy, a rare neurodegenerative disease with no approved disease-modifying treatments. The positive feedback on manufacturing and quality control represents a critical regulatory milestone in developing the first potential therapy to slow disease progression rather than merely manage symptoms.
“Thinking” AI Outperforms Human Doctors on Real-Life Data
A reasoning-based large language model (o1-preview) outperformed human physicians on complex diagnostic reasoning tasks involving real clinical cases, achieving 78.3% accuracy in identifying correct diagnoses and 87.5% accuracy in recommending appropriate diagnostic tests. The performance gap widens on cases requiring synthesis of clinical information and justification of reasoning, suggesting AI systems can augment—or potentially exceed—human diagnostic capability in structured clinical decision-making.
Biological age tests reveal what slows or hastens aging – but they’re useful only for researchers, not consumers
Epigenetic aging clocks measure chemical changes to DNA to estimate biological age, but they are research tools designed for population-level study, not reliable for individual health assessment. Consumer products marketing these tests as personal health indicators misrepresent their validity and clinical utility.
Shared Experience of Physical Vitality and Social Participation Among Caregiving Dyads: Comparing Dyads With and Without Dementia
Caregiving relationships that maintain shared physical activity and social engagement protect against isolation and functional decline in aging adults, with dementia-affected dyads showing particular vulnerability. The structure of caregiving partnerships—whether they preserve mutual participation or devolve into dependency—predicts health trajectories independent of diagnosis.
Scribe highlights CRISPR advances and STX-1150 data at ASGCT, EAS
Scribe Therapeutics is advancing engineered CRISPR platforms, including STX-1150, a liver-targeted epigenetic therapy that achieves sustained LDL-C reduction from a single dose without permanent genomic modification. The technology demonstrates enhanced specificity and potency in cardiometabolic applications, positioning epigenetic approaches as a precision intervention for cardiovascular risk factors.
LifespanningRx launches partner program for peptide therapy
LifespanningRx introduced a Partner Program enabling non-clinical businesses to offer peptide therapy through clinician oversight, pharmacy fulfillment, and white-label infrastructure. This addresses a gap in scalable delivery of peptide-based interventions within the broader precision medicine ecosystem.
#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration
This AMA addresses multiple dimensions of disease prevention and optimization: family history assessment as a risk stratification tool, cardiovascular disease prevention through metabolic and behavioral intervention, strength training efficiency for maintaining muscle mass and metabolic function, dementia risk reduction through modifiable factors, NAD supplementation's role in cellular energy production, and hydration's foundational importance to physiological function. The aggregate effect of these interventions addresses primary prevention across multiple chronic disease pathways relevant to longevity.
Life Stressors and Loneliness in Older Adults: The Role of Family Functioning and Self-Perceptions of Aging
Life stressors correlate with loneliness in older adults, with family functioning and self-perceptions of aging serving as modifiable pathways that influence this relationship. Understanding these associations provides targets for intervention in a population at elevated risk for isolation-related health decline.
Mitigating the Hawthorne effect in aging research
Observation-induced behavioral changes in aging research can produce biomarker shifts equal to or larger than the interventions being tested. This Hawthorne effect is particularly pronounced in geroscience trials and must be methodologically distinguished from genuine biological aging modulation.
The aging extracellular matrix as a missing link in senescent cell accumulation and persistence
Age-related changes to the extracellular matrix create a self-reinforcing cycle that drives senescent cell accumulation and persistence. Senescent cells further degrade the matrix, establishing a pathological feedback loop central to tissue aging.
Vitamin K2 Extends Lifespan by Alleviating Mitochondrial Stress via the JNK‐1/SIR‐2.1/DAF‐16 Signaling Axis in Caenorhabditis elegans
Vitamin K2 at optimal concentrations (5 μM) extends lifespan in C. elegans by activating a signaling pathway that protects mitochondria from oxidative stress, maintains ATP production, and enhances cellular stress resistance. This mechanism operates through preservation of mitochondrial function and reduction of reactive oxygen species accumulation.
Loss of Chromosome Y Associates With Altered Immune Cell Trajectories and X‐Inactivation Features
Loss of chromosome Y in male leukocytes, detected in nearly 9% of cells in older men, produces cell-type-specific immune dysfunction characterized by altered monocyte differentiation and aberrant X-chromosome inactivation patterns. These molecular changes associate with increased risk for cardiovascular disease and cancer, suggesting LOY represents a meaningful driver of age-related immune decline in men rather than a neutral age-related marker.
Disappointing results from the first rapamycin-plus-exercise trial
A randomized controlled trial combining rapamycin and exercise showed no significant improvement in physical function or body composition compared to exercise alone, challenging the hypothesis that mTOR inhibition enhances the adaptive response to resistance training in older adults.
SIRT1 Downregulation by Advanced Glycation End Products Activates RANKL‐Dependent Osteoclast Signaling and Drives Chondrocyte Senescence During Osteoarthritis Development
Advanced glycation end products suppress SIRT1 expression in osteoclasts, triggering RANKL-dependent bone resorption and accelerated chondrocyte senescence—a mechanism that directly couples metabolic stress to cartilage degradation in osteoarthritis. This pathway represents a biochemical link between systemic glucose metabolism and joint degeneration, suggesting that metabolic control earlier in life may alter osteoarthritis trajectory.
The Longevity Investor Network Looks Back at 2025
The Longevity Investor Network deployed over $1.2 million into longevity-focused startups in 2025, continuing its mission to connect early-stage companies in aging biology, regenerative medicine, and senotherapeutics with informed capital. Since 2020, LIN has invested in 23 companies across cellular reprogramming, diagnostics, neurodegeneration, and tissue engineering, demonstrating sustained institutional commitment to translating aging science into commercial solutions.
Deal between Chrysea, nuBioAge brings spermidine to clinics
A partnership between Chrysea Labs and nuBioAge moves spermidine into clinician-guided care through healthcare practitioners and pharmacies, signaling a shift toward evidence-based delivery of longevity interventions within clinical frameworks rather than direct-to-consumer wellness channels. This approach addresses a critical gap: standardized formulations and practitioner guidance that enable reproducible outcomes.
Rejuvenation Roundup April 2026
This April 2026 roundup surveys emerging research across multiple aging pathways: metabolic dysfunction accelerates aging in sedentary populations, enzymatic depletion drives cellular senescence in fat tissue, meal timing influences biological aging rates, and targeted interventions—from NAD+ restoration to immune mobilization via sauna—show measurable effects on muscle, cognition, and immune function in animal models.
The implementation gap
The longevity sector has advanced significantly in bench science yet fails to translate these discoveries into functional health outcomes for aging populations. The gap between cellular research and daily utility for the 60+ demographic represents a critical market and health opportunity that requires repositioning from molecular interventions toward actionable, measurable functional improvements.
NorthStrive addresses muscle loss with EL-22 patent
NorthStrive Biosciences filed a patent for EL-22, a myostatin-engineered probiotic designed to prevent muscle loss in GLP-1 users, aging populations, and post-injury recovery. The filing addresses a critical gap in weight-loss and longevity interventions: preserving muscle composition rather than optimizing weight loss alone.
FDA’s real-time trial push could transform medicine – if they work
The FDA is moving toward real-time clinical trials where safety and efficacy data flows directly to regulators as it is generated, rather than months later after processing. While this approach could accelerate drug approval and patient access, it introduces significant challenges around data integrity, interpretive bias, and the premature pressure to act on incomplete information.
J Craig Venter, PhD: 1946 – 2026
J. Craig Venter, who died at 79, fundamentally altered the pace and methodology of genomic science through high-throughput sequencing, synthetic biology, and later through Human Longevity Inc's integration of genomics with phenotypic data to pursue age-related optimization. His shift from reading the genome to writing it, and his insistence that large-scale data collection could compress discovery timelines, established a template for anticipatory medicine that now defines contemporary longevity research.
BioCardia allowed Japanese patent for Heart3D fusion imaging
BioCardia secured a Japanese patent for Heart3D Fusion Imaging, a software platform that overlays preoperative cardiac imaging onto real-time procedural visualization to guide delivery of autologous cell therapy to damaged heart tissue. This technology bridges the gap between high-resolution anatomical mapping and precise surgical navigation, directly addressing a critical technical barrier in cardiac regenerative medicine.
Insilico gets IND clearance for rentosertib inhalation study
Insilico Medicine obtained investigational new drug clearance for an inhaled formulation of rentosertib, a TNIK inhibitor discovered through AI-driven drug discovery, designed to deliver targeted lung exposure in idiopathic pulmonary fibrosis. The inhalation route enables higher local bioavailability at lower systemic doses, advancing a potential therapeutic for a progressive fibrotic lung condition.
Alector discontinues Phase 2 trial of Nivisnebart in early Alzheimer’s disease
Alector discontinued a Phase 2 trial of Nivisnebart after futility analysis showed insufficient likelihood of slowing Alzheimer's disease progression. This outcome reflects the ongoing challenges in translating progranulin-elevation mechanisms to clinical benefit in early neurodegeneration.
Stealth reports FORZINITY launch momentum and pipeline progress
Stealth reports 33 patients initiated on FORZINITY (elamipretide) for Barth syndrome with 85% coverage and 100% enrollment in patient support programs. The company is pursuing label expansion for younger patients and advancing a pipeline targeting mitochondrial dysfunction across multiple tissues.
Renibus unveils Phase 3 PROTECT data for RBT-1
RBT-1, a single preoperative infusion intended to reduce complications in cardiac surgery patients, failed to meet its primary endpoint in a Phase 3 trial of 433 patients. Post-hoc analysis suggests potential benefit in higher-risk subgroups, though the primary population was predominantly low-risk.
A Decline in Follicle Cell Function Is a Major Driver of Drosophila Ovarian Aging
Follicle cell dysfunction drives ovarian aging in Drosophila through accumulated defects in tissue integrity, genome stability, and germ-soma communication. Enhancing autophagy specifically in follicle cells restores reproductive capacity with age, indicating that somatic cell function is a critical lever in reproductive longevity.